Billiontoone - Class A opened lower at $113.29, compared with its previous close of $114.84. In the last trading session, the stock traded between $110.49 and $113.55. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 1 year ago in Billiontoone - Class A is now worth
$ 102.54
giving a profit of
$ 2.54 (2.54%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-3.14 (-2.73%)
Day High
$113.55
Day Low
$110.49
Day Open
$113.29
Prev Close
$114.84
Volume
2,21,311
1W Return
5.66%
1M Return
-5.54%
3M Return
-15.69%
6M Return
51.54%
1Y Return
2.54%
Fundamentals
Market Cap ($ Mn)
4,763
PE Ratio
148.42
PB Ratio
8.13
PEG Ratio
-
ROE
-
ROCE
0.03%
EPS (TTM)
-
Investment Returns
1 Week
5.66%
1 Month
-5.54%
3 Months
-15.69%
6 Months
51.54%
9 Months
37.55%
Financials
Quarterly
All values in $ Mn
38.4
Sep 24
45.1
Dec 24
66.6
Jun 25
83.5
Sep 25
96.1
Dec 25
109.4
Jun 26
Updates
23Sep
CMS lab fee alignment impacts BillionToOne and CareDx differently
CMS plans to align 2027 Medicare lab rates with private payers to save $1 billion annually. Payment reductions will be phased in capped at 15% annually through 2029. BillionToOne's Northstar Response reimbursement rises 29% to $2,124. CareDx's AlloSure payment increases 3% to $2,840 while AlloMap remains unchanged.
1mo ago
18Aug
BillionToOne publishes NIPT study supporting routine cfDNA use
BillionToOne published a prospective, multi-site study in The Green Journal regarding cell-free DNA testing for recessive conditions. The research is the first of its kind in an intended-use screening population with near-complete outcome ascertainment. It supports the routine use of cfDNA fetal risk assessment in general-risk pregnancies.
2mo ago
6Aug
BillionToOne Q2 Results: Net profit rises to $8.1 million
BillionToOne Inc. turned profitable in Q2 with $8.1 million net income, up from a loss, as revenue surged 64% to $109.4 million. Gross margins hit 70%. Despite maintaining FY26 guidance of $450-465 million and announcing new product launches, shares dropped 28.12% after hours.
2mo ago
29Jun
BillionToOne assay predicts immunotherapy outcomes better than imaging
BillionToOne's Northstar Response assay outperformed standard-of-care imaging in predicting survival for immunotherapy patients, identifying progression a median of 62 days earlier. The study of 142 patients confirmed molecular progression as the dominant independent predictor of survival with a hazard ratio of 5.3.
4mo ago
29Jun
Guggenheim initiates coverage on BillionToOne with Buy rating
Guggenheim analyst Subbu Nambi has initiated coverage on BillionToOne with a Buy rating and established a price target of $125 for the NASDAQ-listed stock.
